Want to see COGT full AI Analyst Report?
COGT Stock Chart & Stats
$37.25
-$0.07(-0.91%)
At close: 4:00 PM EST
$37.25
-$0.07(-0.91%)
Day’s Range― - ―
52-Week Range$10.38 - $43.73
Previous CloseN/A
Volume181.15K
Average Volume (3M)2.99M
Market Cap
$6.58B
Enterprise Value$5.68K
Total Cash (Recent Filing)$866.38M
Total Debt (Recent Filing)$238.65M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 11, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.08
Shares Outstanding170,868,010
10 Day Avg. Volume2,657,211
30 Day Avg. Volume2,990,640
Financial Highlights & Ratios
PEG Ratio-3.81
Price to Book (P/B)3.77
Price to Sales (P/S)0.00
P/FCF Ratio-9.03
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$52.43Price Target Upside40.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$10.85M
Bulls Say, Bears Say
Bulls Say
Focused Precision-medicine PipelineA narrow, genetically defined focus (KIT-driven diseases) supports clearer patient selection, streamlined clinical designs, and potentially higher probability of demonstrating efficacy. Over 2–6 months this remains a durable advantage for partnering, trial enrollment and regulatory planning versus undifferentiated programs.
Balance-sheet Equity CushionSizable equity relative to assets provides a tangible cash and liquidity cushion that can extend runway and support clinical milestones. Moderate leverage gives flexibility to raise capital or pursue collaborations without immediate solvency pressure, a structural strength while programs are pre‑commercial.
Governance And Board ContinuityStrong shareholder support for directors, auditor ratification and pay policies signals governance stability and reduces execution risk. Continuity at the board/oversight level supports consistent strategy, partnership negotiations and credible stewardship of capital over the coming months.
Bears Say
No Revenue And Widening LossesAbsence of operating revenue combined with accelerating net losses means the company remains entirely financing‑dependent. Persistent widening losses reduce flexibility to self‑fund development, increase reliance on dilutive raises or partnerships, and pose a sustained risk to shareholder dilution and strategic optionality.
Heavy, Rising Cash BurnMaterial and increasing operating and free cash outflows erode runway and force near‑term financing decisions. High burn reduces negotiating leverage with partners, can accelerate dilution or debt use, and is a durable constraint on executing clinical programs without new capital or monetization events.
Rising Leverage And Negative ROEAn uptick in debt alongside materially negative returns on equity indicates capital has not translated into shareholder value and raises refinancing risk. Higher leverage narrows financial flexibility, increases cost of capital and magnifies dilution risk if further financing is required to sustain development programs.
Cogent Biosciences News
COGT FAQ
What was Cogent Biosciences, Inc.’s price range in the past 12 months?
Cogent Biosciences, Inc. lowest stock price was $10.38 and its highest was $43.73 in the past 12 months.
What is Cogent Biosciences, Inc.’s market cap?
Cogent Biosciences, Inc.’s market cap is $6.58B.
When is Cogent Biosciences, Inc.’s upcoming earnings report date?
Cogent Biosciences, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 25 days.
How were Cogent Biosciences, Inc.’s earnings last quarter?
Cogent Biosciences, Inc. released its earnings results on May 05, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.533 by $0.003.
Is Cogent Biosciences, Inc. overvalued?
According to Wall Street analysts Cogent Biosciences, Inc.’s price is currently Undervalued.
Does Cogent Biosciences, Inc. pay dividends?
Cogent Biosciences, Inc. does not currently pay dividends.
What is Cogent Biosciences, Inc.’s EPS estimate?
Cogent Biosciences, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Cogent Biosciences, Inc. have?
Cogent Biosciences, Inc. has 170,868,010 shares outstanding.
What happened to Cogent Biosciences, Inc.’s price movement after its last earnings report?
Cogent Biosciences, Inc. reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.533. Following the earnings report the stock price went up 0.681%.
Which hedge fund is a major shareholder of Cogent Biosciences, Inc.?
Currently, no hedge funds are holding shares in COGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogent Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.43 (40.75% Upside)
$52.43 (40.75% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 4.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
247.24%
12-Months-Change
Fundamentals
Return on Equity
-83.29%
Trailing 12-Months
Asset Growth
218.19%
Trailing 12-Months
Company Description
Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
COGT Stock 12 Month Forecast
Average Price Target
$52.43
▲(40.75% Upside)
Technical Analysis
IDEAYA Biosciences
―
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
4.03% Insiders
30.75% Mutual Funds
1.11% Other Institutional Investors
47.55% Public Companies and
Individual Investors